Loading
Cardiovascular Disease and Adiposity / Chronic Kidney Disease and Diabetes · Journal article
Biomolecules · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes mechanistic pathways by which obesity drives chronic kidney disease, mapping adipose depot biology, hormonal axes (RAAS, ghrelin–leptin), and cellular injury to emerging therapies including SGLT2 inhibitors, GLP-1 agonists, finerenone, and aldosterone synthase inhibitors. The review raises mechanistic hypotheses and identifies gaps in conventional RAAS blockade but reports no primary efficacy data, clinical outcomes, or trial results to support specific interventions.
Narrative review. Patients with obesity and chronic kidney disease or obesity-related kidney disease (ORKD) and obesity-related glomerulopathy (ORG); general population mechanism review..
Central, visceral, perirenal and renal-sinus adiposity promote glomerular hyperfiltration, mechanical renal compression, and activation of adipose-derived RAAS. Leptin directly upregulates adrenal aldosterone synthase (CYP11B2), and mast-cell chymase generates angiotensin II independently of ACE, bypassing conventional RAAS blockade. Ghrelin suppression in obesity may withdraw antioxidant, anti-inflammatory and podocyte-protective signals while leptin-driven glomerular injury intensifies.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies underappreciated mechanisms of obesity-related kidney injury (chymase-driven angiotensin II, leptin-mediated aldosterone upregulation, ghrelin suppression) that may not be fully addressed by conventional antihypertensive therapy, suggesting a rationale for mechanism-matched pharmacotherapy and metabolic intervention. Clinicians should note these are proposed mechanisms and candidate biomarkers, not yet validated by outcome trials.
A comprehensive mechanistic review synthesizing evidence on obesity-driven kidney injury pathways and proposing candidate mechanisms and emerging therapies, but presenting no primary data, clinical trial results, or effect sizes to support claims.
As stated by the source record.
This review identifies underappreciated mechanisms of obesity-related kidney injury (chymase-driven angiotensin II, leptin-mediated aldosterone upregulation, ghrelin suppression) that may not be fully addressed by conventional antihypertensive therapy, suggesting a rationale for mechanism-matched pharmacotherapy and metabolic intervention. Clinicians should note these are proposed mechanisms and candidate biomarkers, not yet validated by outcome trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is an increasingly important and modifiable driver of chronic kidney disease (CKD), with effects that extend well beyond its associations with type 2 diabetes, hypertension, and dyslipidemia. To synthesize the evidence that excess adiposity is a causal and modifiable determinant of kidney disease, and to examine how specific adipose depots injure the glomerulus and the tubulointerstitium, and then map these mechanisms onto established and emerging therapies. Throughout, obesity-related kidney disease (ORKD) denotes the full spectrum of diposity-driven renal injury, whereas obesity-related glomerulopathy (ORG) is reserved for the biopsy-defined glomerular lesion. Central, visceral, perirenal and renal-sinus adiposity act first through structural and haemodynamic mechanisms, promoting glomerular hyperfiltration, mechanical renal compression and activation of the adipose-derived renin–angiotensin–aldosterone system (RAAS). In parallel, these depots drive cellular and metabolic injury through lipotoxicity, adipokine imbalance, sterile inflammation, oxidative stress, gut dysbiosis, mitochondrial dysfunction, epigenetic remodelling and cellular senescence. Ectopic lipid accumulation within the renal parenchyma—fatty kidney—offers a unifying description of these changes and is most marked in type 2 diabetes mellitus. These interacting processes converge on podocyte stress, tubular metabolic failure, endothelial dysfunction and interstitial fibrosis, producing a phenotypic continuum that ranges from early albuminuria to obesity-related glomerulopathy and progressive CKD. Within the RAAS limb we highlight two comparatively underappreciated, adiposity-linked routes to injury: adipocyte-derived leptin directly upregulates adrenal aldosterone synthase (CYP11B2), and mast-cell chymase generates angiotensin II independently of angiotensin-converting enzyme, together reinforcing aldosterone- and angiotensin II–mediated damage that conventional RAAS blockade only partially interrupts. We further consider the counter-regulatory ghrelin–leptin axis, in which the suppression of ghrelin that accompanies obesity may withdraw an antioxidant, anti-inflammatory and podocyte-protective signal precisely as leptin-driven glomerular injury intensifies, positioning ghrelin as a plausible modulator and candidate biomarker of obesity-related kidney injury. We also examine how obesity complicates renal risk assessment, drug dosing, dialysis delivery and transplant access. Emerging, mechanism-matched therapies—SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, structured lifestyle intervention, metabolic-bariatric surgery and, most recently, aldosterone synthase inhibitors that suppress the chymase- and leptin-driven aldosterone escaping receptor blockade—now enable a precision cardiovascular-kidney-metabolic framework that aligns adipose-depot biology, biomarkers, histology and treatment response to guide mechanism-based care in ORKD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.